TACE-based combination therapies in the management of intermediate-advanced stage hepatocellular carcinoma
10.3969/j.issn.1008-794X.2025.01.001
- VernacularTitle:中晚期肝细胞癌以TACE为基础的综合治疗
- Author:
Binyan ZHONG
1
;
Gaojun TENG
Author Information
1. 215006 江苏苏州 苏州大学附属第一医院介入科
- Keywords:
hepatocellular carcinoma;
transarterial chemoembolization;
immunotherapy;
systemic therapy
- From:
Journal of Interventional Radiology
2025;34(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Clinically,transarterial chemoembolization(TACE)plays a crucial role in the treatment of intermediate-advanced stage hepatocellular carcinoma(HCC),and it is the most widely used therapeutic approach in clinical practice.Based on the fact that the hypoxic environment inside the tumor after TACE leads to an increase of the vascular endothelial growth factor,thereby increasing the risk of tumor progression,TACE combined with anti-angiogenic agents might theoretically have a synergistic effect.Nevertheless,most trials on this topic have failed.In recent years,immunotherapy-based systemic therapy has made breakthrough in the field of HCC treatment,which not only promotes TACE treatment,but also makes physicians to face the challenges of new general systemic treatment.Considering that the two treatments may have potential synergistic mechanism,the combination use of TACE and immunotherapy-based systemic therapy may be superior to the use of only one of the two treatment methods in improving the curative effect in patients with intermediate-advanced stage HCC.This article aims to make a detailed review about the current evidence in the field of TACE-based combination therapies and to discuss the published and ongoing trials concerning the combination use of TACE and systemic treatments,focusing on the synergistic efficacy and the important role of TACE-based combination therapies in treating patients with intermediate-advanced-stage HCC.
